
    
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the
      safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple
      ascending oral dose administration.

      The study consists of 2 parts: Part 1, SAD dose-escalation; Part 2, MAD dose-escalation.
    
  